The key factors influencing novo-nordisk a/s stock price: the data for the next-generation weight loss drug will be released next month.

Novo Nordisk will release the final clinical trial data of its "next-generation" weight loss drug CagriSema next month. It is expected that CagriSema will be able to reduce the weight of users by 25% in a little over a year, potentially dominating the leading position of GLP-1 class weight loss drugs.

wallstreetcn22:37 ET

The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.

Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.

wallstreetcnNov 17 07:00 ET

Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand? -- Heard on the Street -- WSJ

WSJNov 17 07:00 ET

US Manufacturing Index Rises To 43, Highest Since 2020

Business TodayNov 16 02:13 ET

Top Gap Ups and Downs on Friday: NVO, HSBC, AMAT and More

Moomoo NewsNov 15 18:00 ET · Markets

As RFK Dust Settles, Drug Industry's Response Is Muted -- Barrons.com

Barron'sNov 15 17:03 ET